Newsroom | 210124 results

SAN JOSE, Calif.--(BUSINESS WIRE)--Wonderful Platform, a global leader in AI-enabled aging and dementia-care innovation, today announced the U.S. launch of Avadin™, the world’s first Physical AI Care Operating System, debuting at CES 2026. The company is actively engaging U.S. venture capital firms, insurers, long-term care organizations, and state agencies as it accelerates expansion into the American market. Avadin represents a breakthrough in senior healthcare technology. Instead of treating...

SINGAPORE--(BUSINESS WIRE)--Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stabi...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026. Fol...

ATHÈNES, Grèce--(BUSINESS WIRE)--  COMMUNIQUÉ DESTINÉ UNIQUEMENT AUX MÉDIAS EUROPÉENS SPÉCIALISÉS DANS LES DOMAINES MÉDICAL, PHARMACEUTIQUE ET FINANCIER Genesis Pharma, société biopharmaceutique régionale spécialisée dans la commercialisation de médicaments innovants en Europe centrale et orientale, a annoncé la signature d'un accord de distribution exclusive avec Otsuka Pharmaceutical Europe Ltd. (OPEL), filiale européenne du groupe pharmaceutique mondial Otsuka Pharmaceutical Co., Ltd., conce...

OLYMPIA, Wash.--(BUSINESS WIRE)--The Washington State Health Care Authority (HCA) and Department of Health (DOH) just released a new resource library to help health care providers and emergency medical services (EMS) personnel build knowledge and confidence to prescribe and administer medications for opioid use disorder (MOUD). Powerful MOUD like buprenorphine and methadone can help manage opioid withdrawals and cravings and cut opioid-related deaths by half. Yet, these medications remain under...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has issued a new report and revised its recommendation with respect to STAAR’s merger with Alcon. ISS is now recommending that all STAAR stockholders vote “FOR” STAAR’s amended merger agree...

LONDRES--(BUSINESS WIRE)--Marathon Asset Management (“Marathon”), una empresa especializada en gestión del crédito líder a nivel mundial, que administra más de 24.000 millones de dólares en activos, se complace en anunciar el cierre de una financiación de capital secundario para el Grupo EXALTA ("EXALTA" o la "Empresa"), una empresa de la cartera de Montagu. Marathon se colocó a la cabeza de la financiación, que avaló la creación de EXALTA con la fusión estratégica de tres empresas propiedad de...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

SHANGHAI & NEW YORK--(BUSINESS WIRE)--Shanghai Scizeng Medical Technology Co., LTD, a subsidiary of Changchun GeneScience Pharmaceutical Co., Ltd. (“GenSci”), RTW Investments, LP (“RTW”), and Yarrow Bioscience, Inc. (“Yarrow”) today announced an exclusive global ex-China license agreement for GS-098, a clinical-stage, first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves’ disease (GD) and thyroid eye disease (TED). Fo...

TORONTO--(BUSINESS WIRE)--Cizzle Brands Corporation (Cboe Canada: CZZL; OTCQB: CZZLF; Frankfurt: 8YF) (“Cizzle Brands” or the “Company”), a sports nutrition company that is elevating the game in health and wellness, today announced its financial results for the three months ended October 31, 2025. Q1 FISCAL 2026 HIGHLIGHTS Revenue increased 18% year-over-year to $3.3 million, compared to $2.8 million in Q1 Fiscal 2025 Gross profit of $1.8 million, representing a 54% gross margin Expanded distri...